Diffusion Pharmaceuticals Clinical Trial Of TSC In Brain Cancer Reaches One Year Interim Endpoint
5/15/2014 9:53:20 AM
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Diffusion Pharmaceuticals LLC today announced that it has reached the one year interim endpoint for its Phase I/II clinical trial of trans sodium crocetinate (TSC), the Company’s lead compound for the treatment of cancer. The study enrolled 59 patients with newly diagnosed primary brain cancer (glioblastoma multiforme or GBM) at 18 major U.S. cancer centers. GBM is a deadly cancer, with only 61% of patients alive one year after diagnosis and about 26% at two years. The Diffusion study is designed to determine whether adding TSC to the current standard-of-care treatment for GBM can significantly improve survival.
Help employers find you! Check out all the jobs and post your resume.
comments powered by